Skip to Content
Merck

Y0000802

Dipyridamole for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Dipyridamole

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

2 MG

PLN 670.00

PLN 670.00

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C24H40N8O4
CAS Number:
58-32-2
Molecular Weight:
504.63
NACRES:
NA.24
PubChem Substance ID:
329831157
UNSPSC Code:
41116107
MDL number:
MFCD00010555

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

SMILES string

OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO

InChI key

IZEKFCXSFNUWAM-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

dipyridamole

manufacturer/tradename

EDQM

mp

165-166 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... PDE10A(10846), PDE1A(5136), PDE1B(5153), PDE1C(5137), PDE2A(5138), PDE3A(5139), PDE3B(5140), PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144), PDE5A(8654), PDE6A(5145), PDE6B(5158), PDE6C(5146), PDE6D(5147), PDE6G(5148), PDE6H(5149), PDE7A(5150), PDE7B(27115), PDE8A(5151), PDE8B(8622), PDE9A(5152), SLC29A1(2030)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
D28500001220506BP131
Dipyridamole for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000802

Dipyridamole for peak identification

Dipyridamole European Pharmacopoeia (EP) Reference Standard

D2850000

Dipyridamole

Dipyridamole United States Pharmacopeia (USP) Reference Standard

USP

1220506

Dipyridamole

Dipyridamole British Pharmacopoeia (BP) Reference Standard

BP131

Dipyridamole

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

BP

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

format

neat

format

neat

format

neat

format

neat

API family

dipyridamole

API family

dipyridamole

API family

dipyridamole

API family

dipyridamole

mp

165-166 °C (lit.)

mp

165-166 °C (lit.)

mp

165-166 °C (lit.)

mp

165-166 °C (lit.)

Application

Dipyridamole for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

comparable product

Product No.
Description
Pricing

related product

Product No.
Description
Pricing

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Natalie Crown et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 67(9), 728-733 (2010-04-23)
The safety of fixed-dose combination aspirin-extended-release (ER) dipyridamole for stroke prevention in patients with ischemic heart disease is reviewed. Randomized controlled trials have established the superiority of aspirinER dipyridamole over aspirin alone for secondary stroke prevention. One limitation of this
Subrata Chakrabarti et al.
Vascular pharmacology, 48(4-6), 143-149 (2008-03-18)
Stroke is a leading cause of morbidity and mortality and the most common cause of neurological disability in older individuals. Prevention of recurrent stroke includes risk factor modification as well as the use of therapies that inhibit platelet activation. One
E L L M De Schryver et al.
The Cochrane database of systematic reviews, (2)(2), CD001820-CD001820 (2006-04-21)
Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events (4% to 11% annually). Aspirin reduces that risk by 13%. In one trial, adding dipyridamole to aspirin was associated with a 22% risk-reduction compared with
J Greenhalgh et al.
Health technology assessment (Winchester, England), 15(31), 1-178 (2011-09-06)
Occlusive vascular events such as myocardial infarction (MI), ischaemic stroke and transient ischaemic attack (TIA) are the result of a reduction in blood flow associated with an artery becoming narrow or blocked through atherosclerosis and atherothrombosis. Peripheral arterial disease is
Hyung-Hwan Kim et al.
Arteriosclerosis, thrombosis, and vascular biology, 28(3), s39-s42 (2008-01-05)
Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively. By increasing cAMP and cGMP levels in platelets, DP reversibly
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service